**Mutual Fund Commentary – November 9, 2025**
On November 9, 2025, at 12:13 PM ET, we made the decision to sell Novo Nordisk (NVO) from our portfolio due to concerns that raised questions about the company’s ability to deliver long-term growth.
Our primary concerns stemmed from two key issues. First, there were two incidents of suicide among the 3,008 patients involved in CagriSema’s Phase 3 clinical trials. Second, ongoing challenges related to compounding—an evident violation of intellectual property—pose difficulties that are proving increasingly hard to manage.
Given these factors, we decided it was prudent to exit our position in Novo Nordisk.
The following excerpt is from the Virtus SGA Global Growth Q3 2025 Commentary:
> “In July, we liquidated our position in Novo Nordisk (NVO) (OTCPK: NONOF) and initiated a new position in Fast Retailing.”
We continue to monitor market developments closely, making portfolio decisions that align with our long-term investment strategy.
*This commentary is part of Select Quarterly Mutual Fund Commentaries.*
https://seekingalpha.com/article/4841056-novo-nordisk-continued-concerns-of-compounding?source=feed_all_articles
